Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Olive leaf and mullein: a natural boost for aging brains?

NCT ID NCT07586410

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two food supplements—one made from olive leaf extract and another combining olive leaf with mullein extract—can help maintain memory and thinking skills in older adults with mild cognitive impairment. About 99 participants aged 60–85 will take either one of the supplements or a placebo daily for 6 months. Researchers will measure changes in cognitive function and quality of life, and monitor for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 99 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants of both sexes who meet the following characteristics will be included in the study: * aged between 60 and 85 years; * able to understand and sign the informed consent form; * able to understand and comply with the protocol requirements; * negative HIV test; * score between 20 and 25 on the Montreal Cognitive Assessment (MoCA) questionnaire (Nasreddine et al., 2005). * total Instrumental Activities of Daily Living (IADL) + Activities of Daily Living (ADL) score of 14; * Geriatric Depression Scale (GDS) score between 0 and 5; * Generalized Anxiety Disorder (GAD-7) score between 0 and 4; * not currently taking or taking any medications, including antidiabetics, drugs that affect the nervous system such as antidepressants, anxiolytics, or opioids; * who are not taking antibiotics or have not taken antibiotics in the last four weeks, or in the last 6 months, based on the intensity and duration of antibiotic treatment. Subjects with the following characteristics will be excluded from the study: * aged \< 60 and \> 85 years; * individuals with a MoCA questionnaire score \< 20 and \> 26; * Geriatric Depression Scale (GDS) score \> 5; * Generalized Anxiety Disorder (GAD-7) score \> 4; * who show no willingness to cooperate; * who have difficulty traveling to the referral facility on time; * who are deemed unsuitable by the investigator due to the presence of other conditions deemed incompatible with enrollment and which require pharmacological treatments (e.g., active systemic diseases, diabetes, neurological and psychiatric conditions, including cognitive disorders that prevent completion of the questionnaires); * affected by HIV-acquired immunodeficiency; * individuals with severe visual and hearing impairments; * with known allergies to ingredients of the investigational products (active or placebo); * who abuse alcohol, drugs, nicotine, caffeine, or theine; * who take medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognition disorders in old age are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • COMEGEN Soc. Coop. Sociale, Napoli, 80126

    Naples, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.